ClinicalTrials.gg
TerminatedNCT01217814Updated Sep 1, 2017Results posted

Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers

A Phase 2 interventional study of Sarilumab and Placebo in Rheumatoid Arthritis, sponsored by Sanofi. Terminated at 14 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-09-01.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Why this study was terminated
Due to delay in the study and the impact on the development timelines, not due to any identified safety concerns

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing sarilumab in Arthritis, Rheumatoid — 2 open to participants now, 2 under way, 1 of them phase 3. sarilumab · Arthritis, Rheumatoid.

Enrollment
20th of 22
16 · median 88
Started
2010
with 3 others
Phase 2
Only one
of the 22
Registered
6th of 22
by date
Lead sponsor
14 of 22
Sanofi

Among the 22 studies testing sarilumab in Arthritis, Rheumatoid, this one is the 20th largest by enrollment, is one of 4 that started in 2010, is the only one in phase 2, and was the 6th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 22 studies testing sarilumab in Arthritis, Rheumatoid are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About sarilumab

sarilumab: first FDA approval 2017 (KEVZARA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing sarilumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

Primary Objective:

  • To demonstrate that sarilumab (SAR153191/REGN88) on top of methotrexate (MTX) was superior in efficacy to placebo for the relief of signs and symptoms of rheumatoid arthritis (RA), in participants with active RA who had failed up to 2 tumor necrosis factor-alpha (TNF-α) antagonists.

Secondary Objectives:

  • To assess the safety of sarilumab;
  • To document the pharmacokinetic profile of sarilumab.
Read the detailed description

The duration of the study period for each participant was approximately 22 weeks; including up to 4 weeks screening period, 12-week double-blind treatment period and 6-week safety follow-up period.

Participants who completed the 12-week treatment period were offered enrollment in a separate long-term extension study (LTS11210/NCT01146652).

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of rheumatoid arthritis ≥6 months duration and American College of Rheumatology (ACR) Class I-III functional status at screening and baseline visits;
  • Active disease defined as:

    • At least 6 of 68 tender joints and 6 of 66 swollen joints at screening and baseline visits, and
    • hs-C-Reactive Protein (hs-CRP) >10 g/L or Erythrocyte Sedimentation Rate (ESR) >28 mm/hr at screening visit;
  • Continuous treatment with Methotrexate for at least 12 weeks and on stable dose (minimum 10 mg/week) for at least 6 weeks prior to the screening visit;
  • Participant considered as Primary TNF-α blocker nonresponder. i.e.:

    • Appropriate for previous TNF-α blocker therapy
    • Lack of adequate clinical response after at least 3 months TNF-α blocker therapy with MTX or other synthetic disease modifying anti-rheumatic drug (DMARD) co-therapy.

Exclusion criteria

Exclusion criteria:

  • Age \<18 years or >75 years;
  • Pregnant or breastfeeding woman or woman of , unwilling to utilize adequate or not to become pregnant during the entire study;
  • Fever (>38°C), or chronic, persistent, or recurring infection(s);
  • History of demyelinating disease;
  • Current underlying hepatobiliary disease.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
16 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo 2 mL to match sarilumab once a week (qw) and 0.5 mL to match golimumab every 4 weeks (q4w) on top of MTX (15-25 mg) qw for 12 weeks.

    Drug: Placebo · Drug: methotrexate (MTX) · Drug: Folic/folinic acid

  • Active comparator
    Golimumab 50 mg

    Golimumab 50 mg q4w and placebo (matched to sarilumab) qw on top of MTX (15-25 mg) qw for 12 weeks.

    Drug: Placebo · Drug: Golimumab · Drug: methotrexate (MTX) · Drug: Folic/folinic acid

  • Experimental
    Sarilumab 150 mg

    Sarilumab 150 mg qw and placebo (matched to golimumab) q4w on top of MTX (15-25 mg) qw for 12 weeks.

    Drug: Sarilumab · Drug: Placebo · Drug: methotrexate (MTX) · Drug: Folic/folinic acid

Interventions

  • Pharmaceutical form: solution for injection Route of administration: subcutaneous

    Also known as: SAR153191, REGN88

  • DrugPlacebo

    Pharmaceutical form: solution for injection Route of administration: subcutaneous

  • Pharmaceutical form: solution for injection Route of administration: subcutaneous

    Also known as: Simponi®

  • Pharmaceutical form: tablet or solution for injection Route of administration: Oral (tablet) or subcutaneous, intramuscular (solution)

  • DrugFolic/folinic acid

    Drug page: Leucovorin

    Pharmaceutical form: tablet Route of administration: oral Folic/folinic acid continued according to local standard.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved at Least 20% Improvement in American College of Rheumatology (ACR20) Core Set Disease Activity Index at Week 12

    Time frame: Week 12

Secondary outcomes

  1. Percentage of Participants Who Achieved at Least 50% Improvement in American College of Rheumatology (ACR50) Core Set Disease Activity Index at Week 12

    Time frame: Week 12

  2. Percentage of Participants Who Achieved at Least 70% Improvement in American College of Rheumatology Core (ACR70) Set Disease Activity Index at Week 12

    Time frame: Week 12

  3. Disease Activity Score for 28 Joints (DAS28) at Week 12

    Time frame: Week 12

  4. European League Against Rheumatism (EULAR) Response at Week 12

    Time frame: Week 12

  5. Percentage of Participants Achieving DAS28 Remission Score < 2.6 at Week 12

    Time frame: Week 12

  6. Pharmacokinetic (PK) Parameter: Serum Concentration of Functional and Bound Sarilumab

    Time frame: Week 12

07

Results

Posted Sep 1, 2017
Limitations and caveats
The study was prematurely terminated due to small number of participants entering randomization.

Participant flow

The study was conducted at 10 centers in United States and Europe. A total of 41 participants were screened between 15 November 2010 and 18 May 2011 of whom 16 participants were randomized and 25 were screen failures. Screen failures were mainly due to exclusion criteria met.

Participant flow — Overall Study
MilestonePlaceboGolimumab 50 mgSarilumab 150 mg
Started457
Completed346
Not completed111
Withdrew: Adverse event110
Withdrew: Lack of efficacy001

Outcome measures

PrimaryPercentage of Participants Who Achieved at Least 20% Improvement in American College of Rheumatology (ACR20) Core Set Disease Activity Index at Week 12
Time frame:
Week 12

No measurements were reported for this outcome.

SecondaryPercentage of Participants Who Achieved at Least 50% Improvement in American College of Rheumatology (ACR50) Core Set Disease Activity Index at Week 12
Time frame:
Week 12

No measurements were reported for this outcome.

SecondaryPercentage of Participants Who Achieved at Least 70% Improvement in American College of Rheumatology Core (ACR70) Set Disease Activity Index at Week 12
Time frame:
Week 12

No measurements were reported for this outcome.

SecondaryDisease Activity Score for 28 Joints (DAS28) at Week 12
Time frame:
Week 12

No measurements were reported for this outcome.

SecondaryEuropean League Against Rheumatism (EULAR) Response at Week 12
Time frame:
Week 12

No measurements were reported for this outcome.

SecondaryPercentage of Participants Achieving DAS28 Remission Score < 2.6 at Week 12
Time frame:
Week 12

No measurements were reported for this outcome.

SecondaryPharmacokinetic (PK) Parameter: Serum Concentration of Functional and Bound Sarilumab
Time frame:
Week 12
Reported as:
Mean · ng/mL
Pharmacokinetic (PK) Parameter: Serum Concentration of Functional and Bound Sarilumab
ng/mLSarilumab 150 mg qw
Bound Concentration4271.43 ± 1328.86
Functional Concentration42391.43 ± 26168.68

Adverse events

Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (week 18) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/4 (0%)3/4 (75%)
Golimumab 50 mg—0/5 (0%)1/5 (20%)
Sarilumab 150 mg—0/7 (0%)3/7 (42.9%)
Most frequent other events
Showing 10 of 15
Most frequent other events
EventPlaceboGolimumab 50 mgSarilumab 150 mg
NasopharyngitisInfections and infestations1/40/50/7
SinusitisInfections and infestations1/40/50/7
Urinary tract infectionInfections and infestations1/40/50/7
UrticariaSkin and subcutaneous tissue disorders1/40/50/7
Accidental overdoseInjury, poisoning and procedural complications1/40/51/7
DiarrhoeaGastrointestinal disorders0/41/50/7
VomitingGastrointestinal disorders0/41/50/7
DermatitisSkin and subcutaneous tissue disorders0/41/50/7
InfluenzaInfections and infestations0/40/51/7
HypertensionVascular disorders0/40/51/7

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboGolimumab 50 mgSarilumab 150 mgTotal
Mean45.3 ± 17.962.6 ± 7.654.0 ± 11.154.5 ± 13.2
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboGolimumab 50 mgSarilumab 150 mgTotal
Female43714
Male0202
08

Study locations

14 sites
  • Investigational Site Number 840026
    Freehold, New Jersey 07728, United States
  • Investigational Site Number 840043
    New York, New York 11201, United States
  • Investigational Site Number 840025
    Jackson, Tennessee 38305, United States
  • Investigational Site Number 840038
    Austin, Texas 78705, United States
  • Investigational Site Number 170004
    Barranquilla, Colombia
  • Investigational Site Number 170005
    Barranquilla, Colombia
  • Investigational Site Number 170007
    Bucaramanga, Colombia
  • Investigational Site Number 203002
    Uherske Hradiste, 68601, Czechia
  • Investigational Site Number 380002
    Firenze, 50141, Italy
  • Investigational Site Number 380005
    Genova, 16132, Italy
  • Investigational Site Number 484008
    Durango, 34270, Mexico
  • Investigational Site Number 484002
    Guadalajara, 44690, Mexico
  • Investigational Site Number 724004
    Oviedo, 33006, Spain
  • Investigational Site Number 724002
    Valencia, 46009, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2017, 6 years after primary completion. A results delay was requested in Oct 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2010
First posted
Oct 8, 2010
Start
Nov 2010
Primary completionActual
Sep 2011
CompletionActual
Sep 2011
Results delay requested
Oct 31, 2012
Results first posted
Sep 1, 2017
Last update
Sep 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01217814
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 8, 2010
Start date
Nov 2010
Primary completion
Sep 2011
Completion
Sep 2011
Results posted
Sep 1, 2017
Last update
Sep 1, 2017

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sarilumab

Start the discussion